Clinical Trial Update: Study of Adding AMG 479 to First Line Chemotherapy in Patients With Optimally Debulked Epithelial Ovarian Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial adding AMG 479 to first-line chemotherapy for optimally debulked epithelial ovarian cancer was terminated, with results posted in 2016.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epithelial Ovarian Cancer
• Ovarian Cancer

Drugs mentioned

• AMG 479

Snippet

Sponsor: Translational Research in Oncology | Conditions: Ovarian Neoplasms | Phase 2 | Status: TERMINATED | Results posted: 2016-01-12